10.6-µm Infrared Laser as Adjuvant Therapy for Diabetic Peripheral Neuropathy: a Double-Blind, Randomized Controlled Trial
- Conditions
- Diabetic peripheral Neuropathy
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) diagnosed with DPN in both lower extremities;
(2) aged 18–75 years old, no limit on gender;
(3) delayed nerve conduction velocity in lower extremities;
(4) stable levels of blood glucose level (FPG <= 7.0 mmol/L2hPBG <= 8 mmol/LHbA1c <= 7%);
(5) understanding and signing the informed consent.
(1) neuropathy or chronic pain caused by conditions other than diabetes;
(2) DPN most prevalent in the upper limbs;
(3) Presence of serious medical conditions, including kidney diseases, heart diseases, pulmonary diseases, liver diseases or contagious diseases, or malignant tumors and serious psychopathy;
(4) Previous history of knee/hip replacement surgery or bone fracture of the lower extremities during the last 3 months and other conditions that would confound assessment of neuropathy;
(5) Ulceration and other diseases at the lower extremities;
(6) Acupuncture or moxibustion treatment received in the previous 3 months;
(7) LLLT received in the previous 3 months;
(8) Using other external therapy simultaneously;
(9) Opiate, analgesic, illicit drug or alcohol abuse;
(10) Unwillingness to be randomly assigned into either a treatment or a placebo group;
(11) Unable to fill measurement questionnaires;
(12) Recruited in other clinical trial simultaneously;
(13) Pregnant or breast-feeding women.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method erve Conduction Velocity;
- Secondary Outcome Measures
Name Time Method Michigan Neuropathy Screening Instrument;